IDiyas

For the Inventor, By the Inventor

Mainz, Germany

Ganymed Pharmaceuticals Ag


USPTO Granted Patents = 50



Forward Citations = 436

Loading Chart...
Loading Chart...

120 inventors (with patents filed for the assignee):

goldMedal Ugur Sahin (47 out of 182 patents)

silverMedal Michael Koslowski (33 out of 53 patents)

bronzeMedal Özlem Türeci (26 out of 52 patents)

4.  Ozlem Tureci (20 out of 53 patents)

5.  Dirk Usener (11 out of 19 patents)

6.  Korden Walter (7 out of 18 patents)

7.  Gerd Helftenbein (7 out of 15 patents)

8.  Rita Mitnacht-Kraus (6 out of 16 patents)

9.  Stefan Woll (6 out of 15 patents)

10.  Maria Kreuzberg (6 out of 15 patents)

11.  Harald-Gerhard Geppert (6 out of 10 patents)

12.  Volker Schlüter (6 out of 13 patents)

13.  Stefan Fritz (5 out of 9 patents)

14.  Gunda Brandenburg (5 out of 9 patents)

15.  Bernd Hubner (4 out of 8 patents)


Core Competencies:
Claudin 6
Claudin 18.2
Monoclonal Antibodies
Cancer Diagnosis
Tumor Antigens
Combination Therapy
Immunotherapy
Target-Directed Antibodies
Genetic Products
Tumor Therapy
Cancer Treatment
Epitopes

50 patents:

1. 11345731 - Claudin-6-specific immunoreceptors and t cell epitopes (2022-05-31),
2. 10414824 - Genetic products differentially expressed in tumors and the use thereof (2019-09-17),
3. 10233253 - Antibodies for treatment of cancer expressing claudin 6 (2019-03-19),
4. 10125196 - Monoclonal antibodies for treatment of cancer (2018-11-13),
5. 10093736 - Agents for treatment of claudin expressing cancer diseases (2018-10-09),
6. 10053512 - Antibodies against claudin 18.2 useful in cancer diagnosis (2018-08-21),
7. 10036753 - Identification of surface-associated antigens for tumor diagnosis and therapy (2018-07-31),
8. 10022444 - Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer (2018-07-17),
9. 9932401 - Antibodies specific for claudin 6 (CLDN6) (2018-04-03),
10. 9919036 - Identification of tumor-associated antigens for diagnosis and therapy (2018-03-20),
11. 9902778 - Cancer therapy using CLDN6 target-directed antibodies in vivo (2018-02-27),
12. 9809815 - Methods and compositions for diagnosis and treatment of cancer (2017-11-07),
13. 9775785 - Antibody to genetic products differentially expressed in tumors and the use thereof (2017-10-03),
14. 9770487 - Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma (2017-09-26),
15. 9751934 - Monoclonal antibodies against claudin-18 for treatment of cancer (2017-09-05),
Ganymed Pharmaceuticals AG is a biopharmaceutical company specialized in the research, development, and commercialization of novel antibody-based therapies for cancer treatment. Our mission is to improve the lives of cancer patients through the discovery and delivery of innovative medicines. With our cutting-edge technology and experienced team, we aim to develop targeted therapies that have the potential to revolutionize cancer treatment. Visit our website to learn more about our groundbreaking research and ongoing clinical trials.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

50 Patents

#7 in Mainz

#1,079 in Germany

#13,575 in the World

...
Mainz, Germany

Ganymed Pharmaceuticals Ag

Forward Citations = 436

120 inventors:

goldMedal Ugur Sahin (47 out of 182 patents)

silverMedal Michael Koslowski (33 out of 53 patents)

bronzeMedal Özlem Türeci (26 out of 52 patents)

4.  Ozlem Tureci (20 out of 53 patents)

5.  Dirk Usener (11 out of 19 patents)

Please report any incorrect information to support@idiyas.com
Loading…